Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
James D. Chalmers, Mark L. Metersky, Joseph Feliciano, Carlos Fernandez, Ariel Teper, Andrea Maes, Mariam Hassan, Anjan Chatterjee
Source: ERJ Open Res, 9 (3) 00695-2022; 10.1183/23120541.00695-2022
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
James D. Chalmers, Mark L. Metersky, Joseph Feliciano, Carlos Fernandez, Ariel Teper, Andrea Maes, Mariam Hassan, Anjan Chatterjee. Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis. ERJ Open Res, 9 (3) 00695-2022; 10.1183/23120541.00695-2022
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
|
|